Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Genetically engineered mouse models of cancer can be used to filter genome-wide expression datasets generated from human tumours and to identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNAseq data from tumours arising in two established mouse models of prostate cancer, PB-Cre/PtenloxP/loxP and p53loxP/loxPRbloxP/loxP, and integrated this with published human prostate cancer expression data to pinpoint cancer-associated gene expression changes that are conserved between the two species. To identify potential therapeutic targets, we then filtered this information for genes that are either known or predicted to be druggable. Using this approach, we revealed a functional role for the kinase MELK as a driver and potential therapeutic target in prostate cancer. We found that MELK expression was required for cell survival, affected the expression of genes associated with prostate cancer progression and was associated with biochemical recurrence.

Original publication

DOI

10.15252/emmm.201708274

Type

Journal article

Journal

EMBO Mol Med

Publication Date

03/2018

Volume

10

Keywords

MELK , cross‐species analysis, mouse models, new cancer targets, prostate cancer, Animals, Carcinogenesis, Cell Line, Tumor, Cell Proliferation, Cell Survival, Disease Progression, Down-Regulation, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Genome, Humans, Male, Mice, Molecular Targeted Therapy, Naphthyridines, Neoplasm Invasiveness, Phenotype, Phosphorylation, Prostatic Neoplasms, Protein-Serine-Threonine Kinases, Species Specificity, Spindle Apparatus, Stathmin, Transcriptome